Drug Trial Radar · NCT06834360
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Actual
Start
Feb 6, 2025
Primary completion
Sep 24, 2026
Study completion Feb 17, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older. Study details include: * The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks. * The treatment duration will be up to 52 weeks. * The number of visits will be 9 site visits and 20 phone/home visits.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
Itepekimab (SAR440340)Drug
Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
PlaceboDrug
Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Mometasone furoate nasal spray (MFNS)Drug
Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the endoscopic NPSTime frame: Baseline to Week 24
- Change from baseline in the NCSTime frame: Baseline to Week 24
Locations
111 sites in 23 countries. Site status is shown where the registry gives one.
Excel ENT of Alabama- Site Number : 8400052
Birmingham, Alabama
Velocity Clinical Research - San Diego- Site Number : 8400041
La Mesa, California
Cedars-Sinai Medical Center- Site Number : 8400030
Los Angeles, California
One Of A Kind Clinical Research Center- Site Number : 8400034
Napa, California
University of Florida - Jacksonville- Site Number : 8400053
Jacksonville, Florida
Advanced Research Institute - New Port Richey- Site Number : 8400014
New Port Richey, Florida
University of Illinois at Chicago- Site Number : 8400003
Chicago, Illinois
Advanced ENT & Allergy - Louisville- Site Number : 8400007
Louisville, Kentucky
Velocity Clinical Research - Lafayette- Site Number : 8400026
Lafayette, Louisiana
Johns Hopkins Hospital- Site Number : 8400017
Baltimore, Maryland
University of Cincinnati Medical Center- Site Number : 8400022
Cincinnati, Ohio
Allergy, Asthma and Clinical Research- Site Number : 8400002
Oklahoma City, Oklahoma
Thomas Jefferson University Hospital- Site Number : 8400044
Philadelphia, Pennsylvania
Spartanburg-Greer ENT & Allergy- Site Number : 8400039
Greer, South Carolina
Ear and Sinus Institute- Site Number : 8400048
Fort Worth, Texas
Investigational Site Number : 0320002
Buenos Aires, Argentina
Investigational Site Number : 0320001
Buenos Aires, Argentina
Investigational Site Number : 0320004
Corrientes, Argentina
Investigational Site Number : 0320003
Mendoza, Argentina
Investigational Site Number : 0320005
San Miguel de Tucumán, Tucumán Province, Argentina
Investigational Site Number : 0360003
Bella Vista, New South Wales, Australia
Investigational Site Number : 0360002
Brisbane, Queensland, Australia
Investigational Site Number : 0360001
Spearwood, Western Australia, Australia
Investigational Site Number : 0560006
Alken, Belgium
Investigational Site Number : 0560002
Ghent, Belgium
Investigational Site Number : 0560001
Leuven, Belgium
Investigational Site Number : 0560004
Gesves, Namur, Belgium
Private Practice - Dr. Nelson Rosário- Site Number : 0760001
Curitiba, Paraná, Brazil
Centro de Pesquisa Clínica de Marília - CPCLIM- Site Number : 0760002
Marília, São Paulo, Brazil
Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760005
São José do Rio Preto, São Paulo, Brazil
Clinica de Alergia Martti Antila- Site Number : 0760003
Sorocaba, São Paulo, Brazil
Investigational Site Number : 1240017
Vancouver, British Columbia, Canada
Investigational Site Number : 1240019
Burlington, Ontario, Canada
Investigational Site Number : 1240015
Cambridge, Ontario, Canada
Investigational Site Number : 1240014
Ottawa, Ontario, Canada
Investigational Site Number : 1240003
Québec, Quebec, Canada
Investigational Site Number : 1240012
Québec, Quebec, Canada
Investigational Site Number : 1520001
Concepción, Biobio, Chile
Investigational Site Number : 1520004
Talcahuano, Biobio, Chile
Investigational Site Number : 1520003
Santiago, Reg Metropolitana de Santiago, Chile
Showing 40 of 111 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.